• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ROCHE DIAGNOSTICS TRIGL TRIGLYCERIDES TRIGLYCERIDES GPO WITHOUT FREE GLYCEROL

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ROCHE DIAGNOSTICS TRIGL TRIGLYCERIDES TRIGLYCERIDES GPO WITHOUT FREE GLYCEROL Back to Search Results
Model Number C701
Device Problem Non Reproducible Results (4029)
Patient Problem No Consequences Or Impact To Patient (2199)
Event Date 09/15/2018
Event Type  malfunction  
Manufacturer Narrative
(b)(6).
 
Event Description
The customer stated that they received erroneous results for two samples from the same patient tested with triglycerides on a cobas 8000 c (701) module. The erroneous results were reported outside of the laboratory. The sick patient was at another hospital where trigl results were high (> 50 mmol/l). The patient was treated and the trigl results started to decrease. The patient was then moved to the customer site. The doctor wanted more specific results than > 50, so the lab performed a 1:10 dilution of the patient's samples. Results kept decreasing from 96 mmol/l to 81 mmol/l and then to 73 mmol/l. The customer was concerned with the complained samples since these samples initially resulted with low values which were not flagged. Samples tested after these affected samples had alarms which prompted the analyzer to automatically repeat them. The first complained sample from the patient initially resulted with a trigl value of 6. 44 mmol/l. The sample was diluted 1:10 and repeated, resulting with a trigl value of 61. 71 mmol/l. The sample was repeated without dilution, resulting with a trigl value of 3. 96 mmol/l. The sample result was corrected to > 50 mmol/l. The second complained sample from the patient initially resulted with a trigl value of 5. 25 mmol/l on (b)(6) 2018. The sample was diluted 1:5 and repeated, resulting with a trigl value of 38. 54 mmol/l on (b)(6) 2018. The sample result was corrected to 38. 54 mmol/l. No adverse events were alleged to have occurred with the patient. The trigl reagent lot number is 328103. The reagent expiration date was asked for, but not provided. Upon review of the alarm trace there were approximately 200 abnormal sample clot alarms occurring on different modules on the same line.
 
Manufacturer Narrative
The following medwatch fields have been updated: the patient has a known history of high triglyceride values. Base on review of the reaction monitor of the sample measurement, the specific root cause is most likely related to an extraordinarily high triglyceride concentration on the sample. This causes a depletion of oxygen which is needed for the color reaction this limitation is covered in product labeling.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand NameTRIGL TRIGLYCERIDES
Type of DeviceTRIGLYCERIDES GPO WITHOUT FREE GLYCEROL
Manufacturer (Section D)
ROCHE DIAGNOSTICS
9115 hague road
indianapolis IN 46250 0457
MDR Report Key7939502
MDR Text Key123961125
Report Number1823260-2018-03449
Device Sequence Number1
Product Code CDT
Combination Product (y/n)N
PMA/PMN Number
K873049
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type foreign,health professional,u
Type of Report Initial,Followup
Report Date 10/25/2018
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received10/05/2018
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Device Operator
Device Model NumberC701
Device Catalogue Number05641489001
Device Lot Number328103
Was Device Available for Evaluation? Yes
Was the Report Sent to FDA?
Event Location No Information
Date Manufacturer Received09/19/2018
Is This a Reprocessed and Reused Single-Use Device? No

Patient Treatment Data
Date Received: 10/05/2018 Patient Sequence Number: 1
Treatment
DEXAMETHASONE; PEG-ASPARAGINASE; VINCRISTINE
-
-